Fosun Pharma announced that its subsidiary, Shanghai Henlius Biotech, has received European Commission approval for two new indications for its drug, Serplulimab Injection (Hetronifly®). These approvals cover the first-line treatment of advanced esophageal squamous cell carcinoma and non-squamous non-small cell lung cancer in adult patients under specific conditions. This marks a significant expansion of the drug's therapeutic applications within the European market. AI
RANK_REASON Product approval for a pharmaceutical drug by a major regulatory body. [lever_c_demoted from significant: ic=1 ai=0.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
